[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100581440":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":18,"centralContacts":23,"locations":33,"responsibleParty":53,"collaborators":10,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":60,"acronym":61,"eligibilityCriteria":62,"healthyVolunteers":63,"sex":64,"minAge":65,"maxAge":10,"enrollmentInfo":66,"targetDuration":10,"studyType":69,"phases":10,"briefSummary":70,"conditions":71,"keywords":73,"overallStatus":79,"whyStopped":10,"lastUpdateSubmitDate":80,"lastUpdatePostDateStruct":81,"startDateStruct":84,"completionDateStruct":86,"leadSponsor":88,"locationsCount":89},{"fullName":5,"class":6},"Centre Hospitalier Universitaire de la Guadeloupe","OTHER",[8,12,15],{"label":9,"type":10,"description":11,"interventionNames":10},"SS patients",null,"patients with SS sickle cell disease",{"label":13,"type":10,"description":14,"interventionNames":10},"SC patients","patients with SC sickle cell disease",{"label":16,"type":10,"description":17,"interventionNames":10},"control group AA","patient without sickle cell disease (AA hemoglobin)",[19],{"name":20,"affiliation":21,"role":22},"Veronique Baccini, MD PhD","CHU de la Guadeloupe","STUDY_CHAIR",[24,29],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},"Valérie Hamony Soter","CONTACT","+590590934677","valerie.soter@chu-guadeloupe.fr",{"name":30,"role":26,"phone":31,"phoneExt":10,"email":32},"Mélanie Petapermal","+590590934667","melanie.petapermal@chu-guadeloupe.fr",[34],{"facility":35,"status":10,"city":36,"state":10,"zip":37,"country":38,"countryCode":10,"cosmosGeoPoint":39,"geoPoint":44,"contacts":45},"Chu de La Guadeloupe","Pointe-à-Pitre","97159","Guadeloupe",{"type":40,"coordinates":41},"Point",[42,43],-61.53459,16.23638,{"lat":43,"lon":42},[46,47,48,50],{"name":25,"role":26,"phone":27,"phoneExt":10,"email":28},{"name":30,"role":26,"phone":10,"phoneExt":10,"email":32},{"name":20,"role":49,"phone":10,"phoneExt":10,"email":10},"PRINCIPAL_INVESTIGATOR",{"name":51,"role":52,"phone":10,"phoneExt":10,"email":10},"Maryse Etienne-Julan, MD","SUB_INVESTIGATOR",{"type":54,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100581440","megakaryocyte-heterogeneity-in-sickle-cell-disease-100581440",false,"NCT06850337","Megakaryocyte Heterogeneity in Sickle Cell Disease","Characterization of Megakaryocytic Subpopulations and the \"Immune\" Phenotype of Platelets of the Sickle Cell Disease Patient","MegaDrep","Inclusion Criteria:\n\n* patients with SS or SC SCD\n* diagnosis of SCD performed by electrophoresis or HPLC in a reference laboratory for hemoglobinopathies\n* patients older than 18 years at inclusion\n* clinically in a steady state at inclusion (without complication in the last month and without transfusion in the three last months)\n* patient followed up for SCD at the sickle cell center of Guadeloupe (University hospital of Guadeloupe, Pointe à Pitre)\n* patients who will provide written informed consent in accordance with the Declaration of Helsinki\n* patients affiliated to national social security\n* the control group (AA subjects) will be patients older than 18 years old who come at the University hospital of Guadeloupe, (Pointe à Pitre) for hip or knee replacement and will do not suffer from chronic disease.\n\nExclusion Criteria:\n\n* patients younger than 18 years old\n* patients with hemoglobinopathy other than SS and SC SCD\n* patients with a transfusion therapy or on bleeding therapy for less than three months\n* patients no affiliated to national social security\n* pregnant or breastfeeding patients",true,"ALL","18 Years",{"count":67,"type":68},100,"ESTIMATED","OBSERVATIONAL","Sickle cell disease (SCD) is characterized by chronic hemolytic anemia, painful crisis called vaso-occlusive crisis (VOC) and chronic inflammation. Activated platelets of SCD patients participated to both chronic inflammation and painful VOC. Platelets are anucleated cells from the fragmentation of megakaryocytes in bone marrow.\n\nThe main aim of this study is to characterize the distribution of the different megakaryocyte subpopulations of sickle cell disease patients SS and SC and in particular the \"immune\" megakaryocytes CD148+CD48+ and to compare it with the platelet phenotype.",[72],"Sickle Cell Disease (SCD)",[74,75,76,77,78],"sickle cell disease","immune megakaryocytes","platelets","CD48","CD148","NOT_YET_RECRUITING","2025-05-23",{"date":82,"type":83},"2025-05-25","ACTUAL",{"date":85,"type":68},"2025-07",{"date":87,"type":68},"2027-03",{"name":5,"class":6},1]